# US 10,946,062 B2 · Use of recombinant protein for treating metabolic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,062 B2
- Document ID: US10946062B2
- Status: Granted
- Kind: B2
- Application number: 16/802,171
- Filed: 2020-02-26
- Published: 2020-09-03
- Granted: 2021-03-16
- Earliest claimed: 2019-02-28
- Assignees: Eusol Biotech Co., Ltd.
- Applicants: Eusol Biotech Co., Ltd.
- Inventors: Jin-Ding Huang; Wan-Ya Chang; Che-Ming Yeh
- Web page: https://patentgrep.com/patent/US10946062B2

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/50: Fibroblast growth factor [FGF]
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are methods and compositions useful in preventing or treating a metabolic disorder by using a protein having an amino acid sequence as set forth in SEQ ID NO: 1.

## Claims

### Claim 1

A method for attenuating a level of blood glucose, comprising:
administering to a subject in need thereof a therapeutically effective amount of a protein consisting of the sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the protein is administered subcutaneously, topically, intraneurally, intraperitoneally, intravenously, intramuscularly, intracerebroventricularly or intrathecally.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the protein is administered subcutaneously.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the method is for treating at least one selected from the group consisting of and type II diabetes.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the protein is administered at a dose of 0.01 to 1 mg/kg once or twice a day.